You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

463 Results
Guidelines and Advice
Blog post
We spend an average of one-third of our waking hours at work, so it's important that our workplaces are safe and free from hazards. But for many...
Jan 2019
Regimen
Intent: Adjuvant, Curative
Funding:
Exceptional Access Program
    daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma, based on criteria
Exceptional Access Program
    trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Jun 2025
Regimen
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
  • triptorelin
May 2019
Blog post
The first time Lauri P. met with her fellow patient and family advisors at Cancer Care Ontario, she was unprepared for the emotions stirred up by the...
Mar 2019
Blog post
Jane Smart, Senior Specialist, Technical Training, Legal and Privacy, CCO, shares her unique perspectives of cancer as a patient and as a parent....
Apr 2019
Document
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec.
Apr 2024

Pages